Table 1.
Patient characteristics (intention-to-treat population).
| Characteristic | ICT/CCRT (n = 77) |
CCRT (n = 74) |
p-value |
|---|---|---|---|
| n (%) | n (%) | ||
| Sex | |||
| Male | 70 (90.9) | 70 (94.6) | 0.39 |
| Female | 7 (9.1) | 4 (5.4) | |
| Age | |||
| Mean | 51.2 ± 8.4 | 52.0 ± 8.3 | 0.89 |
| Range | 34–70 | 34–68 | |
| ECOG Performance status | |||
| 0 | 18 (23.4) | 14 (18.9) | 0.73 |
| 1 | 55 (71.4) | 57 (77.0) | |
| 2 | 4 (5.2) | 3 (4.1) | |
| Cancer site | |||
| Oropharynx | 28 (36.4) | 34 (45.9) | 0.09 |
| Hypopharynx | 44 (57.1) | 30 (40.5) | |
| Larynx | 5 (6.5) | 10 (13.5) | |
| Cancer site | |||
| Oropharynx | 28 (36.4) | 34 (45.9) | 0.250 |
| Non-oropharynx | 49 (63.6) | 40 (54.1) | |
| Tumor status | |||
| T1 | 8 (10.4) | 4 (5.4) | 0.41 |
| T2 | 16 (20.8) | 11 (14.9) | |
| T3 | 16 (20.8) | 12 (16.2) | |
| T4A | 27 (35.1) | 34 (45.9) | |
| T4B | 10 (13.0) | 13 (17.6) | |
| Node status | |||
| N0 | 8 (10.3) | 10 (13.5) | 0.02 |
| N1 | 3 (3.9) | 9 (12.2) | |
| N2 | 53 (68.8) | 52 (70.3) | |
| N3 | 13 (16.9) | 3 (4.1) | |
| Stage | |||
| III | 4 (5.2) | 8 (10.8) | 0.37 |
| IVA | 52 (67.5) | 50 (67.6) | |
| IVB | 21 (27.3) | 16 (21.6) | |
| Stage | |||
| III | 4 (5.2) | 8 (10.8) | 0.24 |
| IV | 73 (94.8) | 66 (89.2) | |
| Resectability | |||
| Resectable | 59 (76.6) | 56 (75.7) | 0.83 |
| Unresectable | 18 (23.4) | 18 (24.3) | |
Abbreviations: CCRT: concurrent chemoradiotherapy; ICT/CCRT: induction chemotherapy followed by concurrent chemoradiotherapy; ECOG: Eastern Cooperative Oncology Group.